Context

This transaction involves Charterhouse successfully acquiring a controlling majority stake in SERB. The operation is meticulously structured to perfectly align with the target's existing executive leadership. The historical controlling shareholder and the incumbent management team are significantly reinvesting their proceeds to retain a robust equity position while continuing to lead day-to-day operations. Charterhouse utilizes its latest flagship investment vehicle to capitalize this partnership. The primary strategic rationale underpinning the deal is to massively accelerate SERB's developmental roadmap. The freshly injected capital and strategic guidance will be explicitly deployed to fuel ongoing geographic expansion and aggressively pursue the continuous acquisition of complementary specialty pharmaceutical products and synergistic businesses.

Target

Headquartered in Belgium, SERB is a prominent, independent European pharmaceutical company specializing strictly in niche branded prescription medicines. The firm focuses heavily on highly specific therapeutic areas, including critical and emergency care, neurology, diagnostics, and endocrinology. Operating through multiple established offices across Europe and expanding actively into North America, the company boasts an exceptionally stable and fast-growing product portfolio. Its historical success is deeply rooted in a dual strategic approach: driving robust organic growth while successfully executing targeted acquisitions of niche pharmaceutical products possessing significant growth potential.